Skip to content
DataLookout
Start free
Menu

NCT04807881

Phase Ib Clinical Study of Keynatinib

StatusRecruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved 5 years later.

See at-risk trials from Medolution Ltd.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Oct 10, 2027 to Oct 10, 2032
    • Study completion pushed from Apr 10, 2028 to Apr 10, 2033
    • Eligibility criteria expanded, about 104 words
  2. Primary completion date: Oct 10, 2023 to Oct 10, 2027
    • Study completion date: Apr 10, 2024 to Apr 10, 2028
    v3
  3. Primary completion date: Oct 10, 2022 to Oct 10, 2023
    • Study completion date: Apr 10, 2023 to Apr 10, 2024
    v2
  4. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Objective Response Rate (CR+PR)
Timeframe: Every 2 administration cycles in cycle 1-6 and every 3 administration cycles in cycle 7-n.

Arms and interventions

Keynatinib treatment groupExperimental

Keynatinib, 20 mg，BID

Drugs: Keynatinib

Sites

4 sites in 1 country